Author

A. Viale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 10 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Approach:experimental assay· 6 Research Focus:cancer & tumor microenvironment· 4 Research Focus:differential expression· 4 Assay:scRNA-seq· 3 Assay:spatial transcriptomics· 3 Approach:statistical model· 3 Assay:whole-genome sequencing· 3

Frequent Co-Authors

A. Carugo· 4 shared G. Genovese· 4 shared F. Carbone· 3 shared L. Zhang· 3 shared T. P. Heffernan· 3 shared A. Futreal· 2 shared A. Sgambato· 2 shared A. W. Zhang· 2 shared

Activity by Year

2018-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Carugo

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer

A. W. McPherson, I. Vazquez-Garcia, M. A. Myers, M. Zatzman, D. H. Al-Rawi, A. C. Weiner, S. S. Freeman, N. Mohibullah, G. Satas, M. J. Williams, N. Ceglia, A. W. Zhang, J. Li, J. L. P. Lim, M. Wu, , Ellenso

This study shows that ongoing whole-genome doubling in ovarian cancer promotes cell diversity and immune dysregulation through chromosomal instability and quiescent states.

bioRxiv · Jul 11, 2024 · PreprintCancer Biology

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

Evolutionary fingerprints of EMT in pancreatic cancers

L. Perelli, L. Zhang, S. Mangiameli, A. J. C. Russell, F. Giannese, F. Peng, F. Carbone, C. Le, H. Khan, F. Citron, M. Soeung, T. Lam, S. Lundgren, C. Zhu, D. Catania, , G. Genovese

This study investigates the role of EMT in pancreatic cancer evolution and metastasis, showing that mesenchymal lineages drive chromosomal instability and clonal evolution.

bioRxiv · Sep 18, 2023 · PreprintCancer Biology

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

N. Thongon, F. Ma, P. Lockyer, N. Baran, J. Liu, C. Jackson, A. Rose, B. Wildeman, M. Marchesini, V. Marchica, P. Storti, N. Giuliani, I. Ganan-Gomez, V. Adema, Y. Qing, , S. Colla

This study identifies DNA2 as a key factor in mitochondrial metabolism that enables multiple myeloma cells to survive DNA damage, showing that targeting DNA2 overcomes metabolic reprogramming and enhances therapy effectiveness.

bioRxiv · Feb 22, 2023Cancer Biology

Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes

I. Vazquez-Garcia, F. Uhlitz, N. Ceglia, J. L. P. Lim, M. Wu, N. Mohibullah, A. E. B. Ruiz, K. M. Boehm, V. Bojilova, C. J. Fong, T. Funnell, D. Grewal, E. Havasov, S. Leung, A. Pasha, , Nikolovsk

This study identifies distinct immune and malignant cell phenotypes in ovarian cancer linked to specific mutational processes and anatomic sites.

bioRxiv · Aug 24, 2021Cancer Biology

9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas

F. Carbone, J. K. Huang, L. Perelli, E. Del Poggetto, T. Gutschner, H. Tomihara, M. Soeung, T. N. A. Lam, R. Xia, C. Zhu, X. Song, J. Zhang, K. Sircar, G. G. Malouf, A. Sgambato, , G. Genovese

This study establishes a mouse model of renal cell carcinoma showing that 9p21 loss drives aggressive tumor evolution with chromosomal instability and metastasis.

bioRxiv · Nov 3, 2020 · PreprintCancer Biology

Medium-chain acyl-CoA dehydrogenase, a gatekeeper of mitochondrial function in glioblastoma multiforme

F. Puca, F. Yu, C. Bertolacci, P. Pettazzoni, A. Carugo, E. Huang-Hobbs, J. Liu, C. Zanca, F. Carbone, E. Del Poggetto, J. Gumin, P. Dasgupta, S. Seth, F. F. Lang, E. Sulman, , G. Draetta

This study identifies MCAD as a critical enzyme for fatty acid metabolism in GBM, showing its essential role in preventing mitochondrial damage and apoptosis.

bioRxiv · Sep 28, 2020 · PreprintCancer Biology

Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics

J. L. Rose, S. Srinivasan, W. Yao, S. Seth, M. Peoples, A. Machado, C.-Y. Li, I. L. Ho, J. J. Lee, P. A. Guerrero, E. Kim, M. Syed, J. R. Daniele, A. Deem, M. Kim, , G. F. Draetta

This study introduces CoDEX, a framework that links gene-cluster patterns with genetic vulnerabilities in PDAC, revealing subtype-specific dependencies and their impact on tumor phenotypes.

bioRxiv · Sep 17, 2020 · PreprintCancer Biology

Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer

C. J. Halbrook, G. Thurston, A. McCarthy, B. S. Nelson, P. Sajjakulnukit, A. S. Krall, P. J. Mullen, L. Zhang, S. Batra, A. Viale, B. Z. Stanger, H. R. Cristofk, J. Zhang, M. Pasca di Magliano, C. Jorgensen, C. A. Lyssiotis

The paper identifies two metabolic subclasses in pancreatic cancer cells and shows asparagine's role in supporting proliferation under mitochondrial stress, suggesting a new therapeutic strategy.

bioRxiv · May 15, 2020 · PreprintCancer Biology

The plasmid diversity of Acinetobacter bereziniae HPC229 provides clues on the ability of the species to thrive on both clinical and environmental habitats

M. Brovedan, G. Repizo, P. Marchiaro, A. Viale, A. Limansky

This paper characterizes the plasmid diversity of Acinetobacter bereziniae HPC229, revealing features linked to its adaptation in both clinical and environmental habitats.

bioRxiv · Jul 22, 2019Microbiology

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

J. J. Harding, M. A. Lowery, A. H. Shih, J. M. Schvartzman, S. Hou, C. Famulare, M. Patel, M. Roshal, R. K. G. Do, A. Zehir, D. You, S. D. Selcuklu, A. Viale, M. S. Tallman, D. M. Hyman, , A. M. Intlekofer

The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.

bioRxiv · Aug 1, 2018Cancer Biology